Adaptive Biotechnologies (ADPT) Set to Post Quarterly Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPT) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.0911) per share and revenue of $71.57 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT opened at $26.64 on Monday. The company has a market cap of $4.25 billion, a price-to-earnings ratio of -64.98 and a beta of 2.09. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies has a 12 month low of $12.00 and a 12 month high of $30.74. The stock has a 50-day moving average price of $26.38 and a two-hundred day moving average price of $19.64.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ADPT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Thursday, October 15th. TD Cowen raised their target price on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. The Goldman Sachs Group began coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price target for the company. Finally, Piper Sandler increased their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.06.

Insider Transactions at Adaptive Biotechnologies

In other news, Director Peter Neupert sold 124,690 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the transaction, the director owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. This trade represents a 48.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Chad Robins sold 321,324 shares of Adaptive Biotechnologies stock in a transaction on Monday, August 17th. The stock was sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at approximately $54,687,391.44. This trade represents a 12.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 1,027,001 shares of company stock worth $26,186,445. 5.70% of the stock is currently owned by insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.